QualityStocksNewsBreaks Archives - Page 421 of 1424

ThursdayJun 09, 2022 2:10 pm

QualityStocksNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Expands Portfolio of Rare Cannabinoids with Launch of d9-THCV

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced its launch of B2B sales of the rare cannabinoid delta 9-dominant tetrahydrocannabivarin (“d9-THCV”) into the health and wellness sector via its wholly owned subsidiary, BayMedica LLC. “We are very excited to launch our highly anticipated d9-THCV and further enhance BayMedica’s growing product portfolio,” said Shane Johnson, MD, SVP and general manager of BayMedica. “THCV is one of the few rare cannabinoids that has been researched in early clinical trials for various therapeutic effects, fueling significant interest by end-product manufacturers and consumers alike.…

ThursdayJun 09, 2022 1:16 pm

QualityStocksNewsBreaks – EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQB: EVGIF) Announces Approval of NCIB by TSX Venture Exchange

EverGen (TSX.V: EVGN) (OTCQB: EVGIF), Canada’s renewable natural gas (“RNG”) infrastructure platform, today announced that the TSX Venture Exchange (“TSXV”) has approved the company’s Normal Course Issuer Bid (“NCIB”). The NCIB will allow EverGen to purchase issued and outstanding common shares of EverGen through the facilities of the TSXV during a 12 month period, commencing on June 8, 2022, and ending on June 7, 2023, or such earlier date as EverGen may complete its purchases pursuant to the NCIB or as it may otherwise determine. According to the update, the company implemented the NCIB because it believes that, from time…

ThursdayJun 09, 2022 12:38 pm

QualityStocksNewsBreaks – Odyssey Health Inc. (ODYY) CEO Spotlighted in RedChip Money Report Interview

Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a company focused on developing unique, life-saving medical products, is featured in the latest interview released by the RedChip Money Report and aired on Bloomberg TV. The interview with Odyssey Health CEO Michael Redmond is slated for broadcast at 7 p.m. ET on June 11. During the interview, which is hosted by RedChip CEO Dave Gentry, Redmond discusses the company, including the development of its novel compound, which could be the first FDA-approved treatment for concussions. With more than 5 million concussions reported in the United States each year and an…

WednesdayJun 08, 2022 12:16 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Grants DehydraTECH(TM) License to Ireland-Based AnodGen Bioceuticals

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced the awarding of a five-year, non-exclusive DehydraTECH(TM) license from its wholly-owned subsidiary, Lexaria Pharmaceutical Corp., to AnodGen Bioceuticals of Ireland. According to the update, the awarded license is valid for the manufacturing and distribution of DehydraTECH-processed cannabinoid active pharmaceutical ingredient (“API”) powders within Europe including the U.K., Australia and New Zealand; including pharmaceutical and medical product applications for psychoactive cannabinoids and medical product applications for non-psychoactive cannabinoids. AnodGen, which has the right to manufacture and sell these API powders to third party companies for their own…

WednesdayJun 08, 2022 11:58 am

QualityStocksNewsBreaks – SRAX Inc.’s (NASDAQ: SRAX) Upcoming Event to Highlight Prominent Names and Companies in Decentralized Web Space

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its software-as-a-service (“SaaS”) platform, today announced that the Sequire Decentralized Web Conference will take place on June 23, 2022. As blockchain, DAOs, NFTS and digital currencies take off around the world with far-reaching potential, SRAX is bringing together a list of influential companies making history in this sector for a full day of presentations. Nearly nine million active small-cap investors were invited to the event, which will feature over 15 decentralized web focused companies and keynotes highlighting prominent names in this space.…

WednesdayJun 08, 2022 11:40 am

QualityStocksNewsBreaks – Home Bistro Inc. (HBIS) Engages Alab Group for Brand Strategy Expertise

Home Bistro (OTC: HBIS), a leading online meal delivery platform that offers celebrity chef-inspired, gourmet and lifestyle ready-made meals, today announced that it has retained public relations firm Alab Group, known for its work across hospitality, food and lifestyle initiatives, to assist in the development of new brand strategies. Under the collaboration, Alab will work with an initial focus on Home Bistro to oversee, develop and execute an overarching communication strategy with a secondary phase to support the Model Meals’ brand. “Our new relationship with Alab is extremely important to the company’s continued growth,” said Home Bistro’s Chief Marketing Officer…

TuesdayJun 07, 2022 1:02 pm

QualityStocksNewsBreaks – Eat Well Investment Group Inc.’s (CSE: EWG) (OTC: EWGFF) Products Gaining Increased Distribution Amid Growing Interest in Plant-Based Foods

Eat Well Investment Group (CSE: EWG) (OTC: EWGFF) is “a vertically integrated plant-based foods investment company that has been rapidly building its portfolio of production and distribution brands during the past year to market to growing consumer interest. Bloomberg Intelligence analysis reported expectations that the market will see explosive growth in coming years, forecasting plant-based foods will increase their representation in the global market to 7.7% by 2030 with an exponential increase in valuation to more than $162 billion,” a recent article reads. “Eat Well’s three major investments — ingredients processor Belle Pulses, food creator Sapientia, and baby food brand…

TuesdayJun 07, 2022 12:51 pm

QualityStocksNewsBreaks – Why Odyssey Health Inc. (ODYY) Is ‘One to Watch’

Odyssey Health (OTC: ODYY) is a medical technology company focused on developing lifesaving products that offer technological and clinical advantages over current standards of care. Guided by a senior management team with significant experience relating to refining acquired technologies, building commercial systems, and forging strategic partnerships, the company boasts a diverse development portfolio spanning both pharmaceutical candidates and medical devices. “Odyssey has two pharmaceutical products in development: PRV-002 and PRV-001. PRV-002 is a novel compound for the treatment of concussion, which currently has no FDA-approved drug. In pre-clinical studies, PRV-002 has been shown to significantly improve both neuroscore and memory…

TuesdayJun 07, 2022 11:14 am

QualityStocksNewsBreaks – SPYR Technologies (SPYR) Announces FCC Approval, PTCRB Certification of GeoTraq’s Tracker Module

SPYR (OTCQB: SPYR), a technology company, today announced that its subsidiary GeoTraq’s Tracker Module (“GT-TM100”) is FCC approved and ready for the market. According to the update, the GT-TM100 has successfully completed certification testing required by the PCS Type Certification Review Board (“PTCRB”) and is in compliance with FCC Part 15 Subpart B, Class B (“sDoC”) performance specifications. The PTCRB program provides confidence that devices perform optimally on mobile wireless networks and conform with global standards. “The Tracker Module is a complete, ‘self-contained’ device that can easily be inserted into any device, asset or package to connect it to the…

TuesdayJun 07, 2022 11:00 am

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Acquisition of Entheon Biomedical’s DMT Clinical Study

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has entered an agreement to acquire the largest phase 1 DMT study conducted to date. The acquisition, conducted through Cybin IRL Limited, a wholly owned subsidiary of Cybin, is expected to accelerate Cybin’s CYB004 program timeline by an estimated nine months; CYB004 is Cybin’s proprietary deuterated DMT molecule designed for the potential treatment of anxiety disorders.. The phase 1 N,N-dimethyltryptamine (“DMT”) study is focused on evaluating pharmacokinetics/pharmacodynamics of DMT currently underway and is expected to significantly impact the clinical path forward. Renamed CYB004-E, the phase 1 EBRX-101…

Site Search

Company Search

Category: QualityStocksNewsBreaks